FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release SyndromeRobert Q. Le, Richard Pazdur, Lei Nie et al.|The Oncologist|2018Cited by 880
FDA Approval Summary: Dabrafenib in Combination with Trametinib for <i>BRAF</i>V600E Mutation–Positive Low-Grade GliomaMichael I. Barbato, Nicole Drezner, Jeannette Nashed et al.|Clinical Cancer Research|2023Cited by 70